Bioimplants Market By Type (Cardiovascular bioimplants, Dental bioimplants, Orthopedic bioimplants, Spinal bioimplants, Ophthalmology bioimplants, Other bioimplants), By End User (Hospitals, Specialty clinics, Ambulatory surgical centers): Global Opportunity Analysis and Industry Forecast, 2024-2035
The global bioimplants market was valued at $132.80 billion in 2023 and is projected t%li%reach $364.8 billion by 2035, growing at a CAGR of 8.8% from 2024 t%li%2035. Bioimplants, als%li%known as biomedical implants, are devices or tissues that are placed inside or on the surface of the body t%li%replace or support biological structures, monitor bodily functions, deliver drugs, or provide therapeutic interventions. These implants are designed t%li%integrate seamlessly with the body's tissues and systems, aiming t%li%improve health outcomes and quality of life for individuals with various medical conditions. Bioimplants can be made from a variety of materials, including metals, ceramics, polymers, and biological substances such as tissues or cells. They are utilized in a wide range of medical applications, including orthopedics (such as hip or knee replacements), cardiovascular interventions (such as stents or pacemakers), neurology (such as deep brain stimulation devices), and even in cosmetic surgery (such as breast implants).
The bioimplants market growth is attributed t%li%rise in geriatric population, surge in prevalence of cardiovascular diseases, and technological advancement in bioimplant technology. The rise in the geriatric population stands as a significant driver propelling the bioimplants market forward. With advancements in healthcare and improvements in overall quality of life, people are living longer than ever before. As a result, there has been a notable increase in the proportion of elderly individuals within the global population. According t%li%World Health Organization it was estimated that by 2050 proportion of the world's population over 60 years will be 22% of global population.Elderly individuals often face challenges such as degenerative joint diseases, weakened bones, and deteriorating dental health, necessitating interventions such as joint replacements, bone grafts, and dental implants. Bioimplants offer innovative approaches t%li%restore functionality, alleviate pain, and improve the overall quality of life for these patients. Furthermore, as the geriatric population continues t%li%grow, the demand for bioimplants is expected t%li%escalate correspondingly, driving market expansion. Thus, the rise in geriatric population is expected t%li%drive the growth of the market.The surge in cardiovascular diseases has emerged as a significant driving force propelling the growth of bioimplants market. According t%li%2023 article by Center of Disease Control and Prevention it was reported that Heart disease is the leading cause of death for men, women in U.S. With cardiovascular diseases increasingly prevalent globally, there has been a heightened demand for innovative solutions t%li%address these conditions effectively. Bioimplants, which encompass a range of devices such as pacemakers, stents, and artificial heart valves, play a pivotal role in managing and treating cardiovascular ailments. These implants offer several advantages over traditional treatments, including improved longevity, reduced risk of complications, and enhanced patient outcomes. Moreover, advancements in biomaterials and biotechnology have led t%li%the development of bioimplants that closely mimic natural tissues, promoting better integration within the body and minimizing the risk of rejection. As a result, healthcare providers are increasingly turning t%li%bioimplants as a preferred option for managing cardiovascular diseases, driving the growth of the marketTechnological advancements have emerged as a pivotal force propelling the growth of the bioimplants market. These advancements encompass a spectrum of innovations, ranging from materials science t%li%miniaturization and advanced manufacturing techniques. One significant stride lies in the development of biomaterials with enhanced biocompatibility, durability, and functionality. These materials, such as biodegradable polymers and bioactive ceramics, enable seamless integration with biological systems, reducing the risk of rejection and improving long-term outcomes for patients. Moreover, advancements in additive manufacturing, commonly known as 3D printing, have revolutionized the production of custom-designed implants tailored t%li%individual patient anatomy. This not only enhances the efficacy of implants but als%li%streamlines the surgical process, reducing operating time and minimizing post-operative complications. As these technological innovations continue t%li%evolve, they hold the promise of further expanding the application and efficacy of bioimplants across diverse medical fields.The bioimplants market is segmented on the basis of type, end user, and region. By type the market is divided int%li%cardiovascular bioimplants, dental bioimplants, orthopedic bioimplants, spinal bioimplants, ophthalmology bioimplants, other bioimplants. By end user, the market is classified int%li%hospital, specialized clinics, and ambulatory surgical centers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).Major key players that operate in the bioimplants market are Medtronic plc, Stryker Corporation, Johnson & Johnson (Ethicon, Inc.), Abbott Laboratories (St. Jude Medical, Inc.), Dentsply Sirona Inc, Boston Scientific Corporation, Victrex Plc. (Invibi%li%Ltd.), Smith & Nephew plc, Arthrex, Inc, Zimmer Biomet Holdings Inc. Key players have adopted product approval as a key developmental strategy t%li%improve the product portfoli%li%of the bioimplants market
Key Benefits For Stakeholders
By Type
The bioimplants market growth is attributed t%li%rise in geriatric population, surge in prevalence of cardiovascular diseases, and technological advancement in bioimplant technology. The rise in the geriatric population stands as a significant driver propelling the bioimplants market forward. With advancements in healthcare and improvements in overall quality of life, people are living longer than ever before. As a result, there has been a notable increase in the proportion of elderly individuals within the global population. According t%li%World Health Organization it was estimated that by 2050 proportion of the world's population over 60 years will be 22% of global population.Elderly individuals often face challenges such as degenerative joint diseases, weakened bones, and deteriorating dental health, necessitating interventions such as joint replacements, bone grafts, and dental implants. Bioimplants offer innovative approaches t%li%restore functionality, alleviate pain, and improve the overall quality of life for these patients. Furthermore, as the geriatric population continues t%li%grow, the demand for bioimplants is expected t%li%escalate correspondingly, driving market expansion. Thus, the rise in geriatric population is expected t%li%drive the growth of the market.The surge in cardiovascular diseases has emerged as a significant driving force propelling the growth of bioimplants market. According t%li%2023 article by Center of Disease Control and Prevention it was reported that Heart disease is the leading cause of death for men, women in U.S. With cardiovascular diseases increasingly prevalent globally, there has been a heightened demand for innovative solutions t%li%address these conditions effectively. Bioimplants, which encompass a range of devices such as pacemakers, stents, and artificial heart valves, play a pivotal role in managing and treating cardiovascular ailments. These implants offer several advantages over traditional treatments, including improved longevity, reduced risk of complications, and enhanced patient outcomes. Moreover, advancements in biomaterials and biotechnology have led t%li%the development of bioimplants that closely mimic natural tissues, promoting better integration within the body and minimizing the risk of rejection. As a result, healthcare providers are increasingly turning t%li%bioimplants as a preferred option for managing cardiovascular diseases, driving the growth of the marketTechnological advancements have emerged as a pivotal force propelling the growth of the bioimplants market. These advancements encompass a spectrum of innovations, ranging from materials science t%li%miniaturization and advanced manufacturing techniques. One significant stride lies in the development of biomaterials with enhanced biocompatibility, durability, and functionality. These materials, such as biodegradable polymers and bioactive ceramics, enable seamless integration with biological systems, reducing the risk of rejection and improving long-term outcomes for patients. Moreover, advancements in additive manufacturing, commonly known as 3D printing, have revolutionized the production of custom-designed implants tailored t%li%individual patient anatomy. This not only enhances the efficacy of implants but als%li%streamlines the surgical process, reducing operating time and minimizing post-operative complications. As these technological innovations continue t%li%evolve, they hold the promise of further expanding the application and efficacy of bioimplants across diverse medical fields.The bioimplants market is segmented on the basis of type, end user, and region. By type the market is divided int%li%cardiovascular bioimplants, dental bioimplants, orthopedic bioimplants, spinal bioimplants, ophthalmology bioimplants, other bioimplants. By end user, the market is classified int%li%hospital, specialized clinics, and ambulatory surgical centers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).Major key players that operate in the bioimplants market are Medtronic plc, Stryker Corporation, Johnson & Johnson (Ethicon, Inc.), Abbott Laboratories (St. Jude Medical, Inc.), Dentsply Sirona Inc, Boston Scientific Corporation, Victrex Plc. (Invibi%li%Ltd.), Smith & Nephew plc, Arthrex, Inc, Zimmer Biomet Holdings Inc. Key players have adopted product approval as a key developmental strategy t%li%improve the product portfoli%li%of the bioimplants market
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bioimplants market analysis from 2023 t%li%2035 t%li%identify the prevailing bioimplants market opportunities.
- The market research is offered along with information related t%li%key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers t%li%enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the bioimplants market segmentation assists t%li%determine the prevailing market opportunities.
- Major countries in each region are mapped according t%li%their revenue contribution t%li%the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global bioimplants market trends, key players, market segments, application areas, and market growth strategies.
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk t%li%the sales executive t%li%know more)
- Regulatory Guidelines
- Additional company profiles with specific t%li%client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
By Type
- Dental bioimplants
- Orthopedic bioimplants
- Spinal bioimplants
- Ophthalmology bioimplants
- Cardiovascular bioimplants
- Other bioimplants
- Hospitals
- Specialty clinics
- Ambulatory surgical centers
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Stryker Corporation
- Medtronic plc
- Smith & Nephew plc
- Dentsply Sirona Inc.
- Johnson & Johnson
- Victrex plc
- Zimmer Biomet Holdings Inc.
- Boston Scientific Corporation
- Abbott Laboratories
- Arthrex, Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: BIOIMPLANTS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Cardiovascular bioimplants
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Dental bioimplants
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Orthopedic bioimplants
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Spinal bioimplants
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Ophthalmology bioimplants
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
4.7. Other bioimplants
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market share analysis by country
CHAPTER 5: BIOIMPLANTS MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Specialty clinics
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Ambulatory surgical centers
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: BIOIMPLANTS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Type
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Type
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Type
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Type
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Type
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Type
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Type
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Type
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Type
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Type
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Type
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Type
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Type
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Type
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. India
6.4.4.3.1. Market size and forecast, by Type
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. Australia
6.4.4.4.1. Market size and forecast, by Type
6.4.4.4.2. Market size and forecast, by End User
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Type
6.4.4.5.2. Market size and forecast, by End User
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Type
6.4.4.6.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Type
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Type
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Type
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Type
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Type
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Stryker Corporation
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Medtronic plc
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Smith & Nephew plc
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Dentsply Sirona Inc.
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Johnson & Johnson
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Victrex plc
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Zimmer Biomet Holdings Inc.
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Boston Scientific Corporation
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Abbott Laboratories
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Arthrex, Inc.
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: BIOIMPLANTS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Cardiovascular bioimplants
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Dental bioimplants
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Orthopedic bioimplants
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Spinal bioimplants
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Ophthalmology bioimplants
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
4.7. Other bioimplants
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market share analysis by country
CHAPTER 5: BIOIMPLANTS MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Specialty clinics
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Ambulatory surgical centers
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: BIOIMPLANTS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Type
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Type
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Type
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Type
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Type
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Type
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Type
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Type
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Type
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Type
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Type
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Type
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Type
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Type
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. India
6.4.4.3.1. Market size and forecast, by Type
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. Australia
6.4.4.4.1. Market size and forecast, by Type
6.4.4.4.2. Market size and forecast, by End User
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Type
6.4.4.5.2. Market size and forecast, by End User
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Type
6.4.4.6.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Type
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Type
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Type
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Type
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Type
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Stryker Corporation
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Medtronic plc
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Smith & Nephew plc
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Dentsply Sirona Inc.
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Johnson & Johnson
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Victrex plc
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Zimmer Biomet Holdings Inc.
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Boston Scientific Corporation
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Abbott Laboratories
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Arthrex, Inc.
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
